title: [C-ANCA positive necrotising scleritis and multiple sclerosis compatible with ocular Wegener: treatment with rituximab].
abstract: METHODS
  A patient diagnosed with necrotizing scleritis, c-ANCA+ an orbital pseudotumour, and possible multiple sclerosis in 2003 was treated with oral cyclophosphamide and steroids with partial response. Between 2005-2010 she suffered self-limited episodes. In 2010 a first scleral transplant was performed with poor outcome. She was treated with rituximab, and a second graft was performed with good results. At 12 months there was no change in magnetic resonance and the second graft healed.
  
  
  CONCLUSIONS
  Wegener's disease with limited involvement of the orbit and/or the eye is a rare condition. The histopathology, blood analysis, symptoms and good response to treatment are the key to its diagnosis.
authors.affiliation: Sección de Reumatología, Clínica Universidad de Navarra, Pamplona, España. Electronic address: vicentealdasoro@hotmail.com.
authors.forename: V
authors.initials: V
authors.lastname: Aldasoro-Cáceres
authors.affiliation: Servicio de Oftalmología, Hospital Universitario de Cruces, Bilbao, Bizkaia, España.
authors.forename: I
authors.initials: I
authors.lastname: Aldasoro-Cáceres
authors.affiliation: Servicio de Neurología, Clínica Oftalmológica Moreiras, A Coruña, España.
authors.forename: J V
authors.initials: JV
authors.lastname: Pérez-Moreiras
authors.affiliation: Sección de Reumatología, Clínica Universidad de Navarra, Pamplona, España.
authors.forename: M
authors.initials: M
authors.lastname: Murié-Fernández
authors.affiliation: Unidad de Reumatología, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: R
authors.initials: R
authors.lastname: Ibáñez-Bosch
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000134:cerebrospinal fluid / Q000150:complications* / Q000175:diagnosis; D043025:Oligoclonal Bands / Q000134:cerebrospinal fluid; D016727:Orbital Pseudotumor / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D012590:Sclera / Q000637:transplantation; D015423:Scleritis / Q000209:etiology* / Q000601:surgery
chemical_list: D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D043025:Oligoclonal Bands; D000069283:Rituximab; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Esclerosis múltiple; Granulomatosis de Wegener; Multiple sclerosis; Orbital seudotumour; Rituximab; Seudotumor orbitario; Systemic vasculitis; Vasculitis sistémica; Wegeneŕs granulomatosis